Arpeggio Bio
Jenna received her PhD from the University of Colorado where she focused on the mechanisms of RNA Pol II mediated transcription and collaborated with Syros Pharmaceuticals on a novel CDK7 inhibitor. At Arpeggio, Jenna focuses on target discovery and validation for transcriptional addiction mechanisms in cancer.
Arpeggio Bio
Arpeggio Bio's technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment.